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Abstract
Background: Observational studies have documented a potential protective effect of physical exercise in older
adults who are at risk for developing Alzheimer’s disease. The Fitness for the Ageing Brain II (FABS II) study is a
multicentre randomized controlled clinical trial (RCT) aiming to determine whether physical activity reduces the
rate of cognitive decline among individuals with Alzheimer’s disease. This paper describes the background,
objectives of the study, and an overview of the protocol including design, organization and data collection
methods.
Methods/Design: The study will recruit 230 community-dwelling participants diagnosed with Alzheimer’s disease.
Participants will be randomly allocated to two treatment groups: usual care group or 24-week home-based
program consisting of 150 minutes per week of tailored moderate physical activity. The primary outcome measure
of the study is cognitive decline as measured by the change from baseline in the total score on the Alzheimer’s
disease Assessment Scale-Cognitive section. Secondary outcomes of interest include behavioral and psychological
symptoms, quality of life, functional level, carer burden and physical function (strength, balance, endurance,
physical activity). Primary endpoints will be measured at six and twelve months following the baseline assessment.
Discussion: This RCT will contribute evidence regarding the potential benefits of a systematic program of physical
activity as an affordable and safe intervention for people with Alzheimer’s disease. Further, if successful, physical
activity in combination with usual care has the potential to alleviate the symptoms of Alzheimer’s disease and
improve its management and the quality of life of patients and their carers.
Trial Registration: Australia New Zealand Clinical Trials Registry ACTRN12609000755235
Background
Advancing age increases the risk of dementia [1], of
which Alzheimer’s disease (AD) is the most common
cause. Available projections indicate that the number of
people with dementia worldwide will increase from 35.6
million in 2010 to 115.4 million people by 2050 [2],
with dementia expected to become the major social and
economic health challenge of the 21
st century.
Alzheimer’s disease is characterized by a progressive
deterioration in memory and other higher cortical func-
tions that ultimately leads to a loss of independent living
skills [3]. Despite the availability of palliative medication
with cholinesterase inhibitors and memantine [4], there
is currently no cure for AD. There is growing evidence
that some environmental factors such as physical and
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any medium, provided the original work is properly cited.cognitive activity [5,6], decrease the risk of AD [7] and
improve the behaviour of patients [8], but it is unclear if
such lifestyle interventions can also delay the progres-
sion of cognitive decline once the diagnosis of AD has
been established [9].
Prospective cohort studies indicate that PA is asso-
ciated with reduced incidence of dementia [10]. Middle-
ton et al. [11] reported that women who were physically
active across the life course had a lower prevalence of
cognitive impairment in later life. The association
between PA and cognitive function was evident even
when exercise is limited to later life [12]. However, as
Leone et al. [13] noted, these findings are limited by
methodological issues such as survivorship bias and con-
founding, the latter arising because the exposure to PA
is not random in observational studies.
A recent randomised trial (RCT) showed that six
months of PA decreased the rate of cognitive decline in
older people with subjective memory complaints or
Mild Cognitive Impairment (MCI) [14], a group that is
at increased risk of developing AD [15]. Subsequently,
Baker and colleagues [16] found that six months of
high-intensity aerobic activity (75-85% of heart rate
reserve) improved executive control processes in seden-
tary women with MCI. Possible mechanisms mediating
the cognitive enhancing effect of PA include alterations
of cerebral vascular functioning and brain perfusion,
environment enrichment and stimulation of synaptogen-
esis [14]. A Cochrane review of PA trials for individuals
with MCI is currently under way [17].
Few RCTs of PA in AD have been published to date.
Most evidence in this area comes from studies conducted
with nursing home residents or participants with moder-
ate to severe AD, and the primary outcomes of interest
tend to be functional status and/or mood [8,18-20]. The
intervention provided in the largest trial, with 134 partici-
pants from five nursing homes, was a group-based multi-
component exercise program [18]. After 12 months, par-
ticipants in the exercise group experienced a slower
decline in their performance of activities of daily living
than those in the control group, but there was no change
in behavioural or psychological symptoms (BPSD). In a
pilot RCT, Steinberg et al. [19] examined the effect of a
home-based, carer-supervised program of walking,
strength training and balance exercises on cognition, sec-
ondary to measures of functional performance, in 27 peo-
ple with AD. Although the small sample size likely
precluded finding any significant differences between
groups in cognitive functioning, the investigators found
that the exercise program was safe, could be supervised
by caregivers and had good compliance.
The objectives of the present study are to conduct a
methodologically rigorous RCT investigating the poten-
tial benefits of PA on cognition, well-being, function and
BPSD in community-dwelling participants diagnosed
with mild to moderate AD. We will also examine
whether the intervention eases stress and burden of care,
an area that is often neglected in such RCTs [21]. This
paper describes the design of the Fitness for the Ageing
Brain Study II (FABS II).
Methods/Design
Study Design
FABS II is a single blind RCT (Figure 1). The CON-
SORT statement has been used as a framework for
development of the methodology for this project.
Participants
230 community-dwelling older adults diagnosed with
AD will be recruited across three sites in Australia
Figure 1 Study Design.
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included in the study if they satisfy the following cri-
teria: (i) diagnosed with probable or possible AD accord-
ing to NINCDS-ADRDA criteria [3], (ii) score of 10 or
greater on the Standardised Mini Mental State Examina-
tion (SMMSE) [22], (iii) community dwelling, (iv) no
clinically significant depression, (v) understands written
and spoken English, (vi) contact with a friend or family
member (carer) for at least 10 hours per week, who is
also willing to participate in the trial, and (vii) no other
major neurological history or medical condition that
contraindicates PA.
Participants will be excluded if they have limited
mobility (e.g. unable to walk alone or require a walking
aid for balance), show evidence of clinically significant
aphasia or pervasive depression, current history of
alcohol dependence, have an unstable or life-threaten-
ing medical condition, or are participating in another
RCT.
Diagnosis of AD will be confirmed through medical
records obtained from the participant’s treating general
practitioner and specialist. These records will be
reviewed by members of the research team who are
either experienced Geriatricians or Old Age Psychiatrists
to confirm the participant’s suitability for inclusion.
This study is funded by the National Health and Med-
ical Research Council of Australia. Ethics approval has
been obtained from the Human Research Ethics Com-
mittee(s) of each participating site and the project com-
plies with the Declaration of Helsinki.
Recruitment and Screening
Potential participants and their carers will be identified
and recruited via local physicians, Memory Clinics and
specialists. Additionally, flyers advertising the study and
media activities will invite suitable older adults living in
the community to consider participation. The research
team will contact the participant and next of kin by tele-
phone to check the suitability of the participant accord-
ing to the study inclusion and exclusion criteria using a
strict screening protocol. The 15-item Geriatric Depres-
sion Scale (GDS - 15) [23] is included as part of the
phone screening to establish the presence of clinically
relevant symptoms of depression, excluding potential
participants with a score of 6 and higher. The name and
contact details for the participant’s GP and specialist
will be obtained, and the participant will be asked to
sign and return a release of medical information form to
allow the study team to access their medical records.
The participant’s GP will also be asked to consent to
their patient’s involvement in the study. This is another
way of determining the suitability of FABS II for the
potential participant and ensuring his/her safety during
the course of the trial.
Assessments
Participants will be assessed at baseline and after six
months and twelve months in the study (see Table 1 for
an overview). There will be two components to the
assessments comprising cognitive measures and physical
function measures/physical activity questionnaires.
Unless stated otherwise, all measures will be adminis-
tered at each time point. The research assistant (RA)
administering the cognitive assessment (Cognitive RA)
will be trained by either a Geriatrician or an Old Age
Psychiatrist at each site. To ensure that the Cognitive
RA remains blind to study group allocation, the physical
assessments will be conducted by a separate PA RA.
The PA RA will collect demographic and health infor-
mation via participant interview. The PA RA at each
site will be trained by the same chief investigator with a
background in exercise physiology to ensure standardi-
zation of procedures across all three sites.
Measures administered by the Cognitive RA
The total score on the Alzheimer’s disease Assessment
Scale - Cognitive section (ADAS-cog) [24] will be the
primary outcome measure of the study. The ADAS-cog
consists of an 11-item battery of short neuropsychologi-
cal tests and is widely used to monitor the progression
of cognitive deficits in clinical trials with patients with
AD. Here we will use a version incorporating a delayed
verbal recall task. Higher scores indicate increased
severity of cognitive impairment (maximum score is 85).
The following nine assessments comprise the second-
ary outcome measures. The Cambridge Contextual
Reading Test (CCRT) [25] includes the words of the
National Adult Reading Test (NART), embedding them
within appropriate semantic and syntactic contexts to
provide a reliable measure of pre-morbid intelligence.
The CCRT is only administered at baseline.
The SMMSE [22] is a modified version of the tradi-
tional MMSE [26], which benefits from greater objectiv-
ity through more specific scoring examples as well as
alternatives for repeated testing of the registration and
delayed recall items. A score of less than 10 on the
SMMSE will be used to exclude participants, as these
individuals would most likely be too cognitively
impaired to follow the intervention instructions.
The Clinical Dementia Rating Scale (CDR) [27] is a
global rating scale for dementia incorporating informa-
tion from the primary carer across the domains of
memory, orientation, judgment and problem-solving,
community affairs, home and hobbies, and personal
care. The subscores on each domain are ranked accord-
ing to severity and an algorithm is used to compute the
total score.
The Quality of Life in AD (QoL-AD) [28] is a 13-item
questionnaire which requires the participant and carer
to independently rate the participant’s quality of life
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poor (1 point) to excellent (4 points).
The Neuropsychiatric Inventory (NPI) [29] is a well-
established assessment of 12 different BPSD common in
AD including delusions, hallucinations, agitation,
depression, anxiety, euphoria, apathy, disinhibition, irrit-
ability, aberrant motor behaviour, night-time behaviour,
appetite and eating disorders. The carer rates each
symptom according to the frequency and severity as
well as the degree of distress the symptom causes them.
The Instrumental Activities of Daily Living scale (IADL)
[30] is widely used to assess independent living skills and
is useful in identifying improvement or deterioration over
time. The carer rates the AD participant across eight func-
tional abilities, including use of the telephone, shopping,
food preparation, housekeeping, laundry, mode of trans-
port, taking medications and handling finances.
The Index of Independence in Activities of Daily Liv-
ing scale (ADL) [31] is a six-item questionnaire where
the carer is required to rate personal and domestic
ADLs such as bathing, dressing, toileting, transfers, con-
tinence, and feeding. The number of activities in which
the participant is deemed ‘dependent’ is counted.
The Short Form-36v2 [32] is a 36-item questionnaire
that assesses the health and well-being of the carer across
eight dimensions; physical functioning, social functioning,
role limitations due to physical problems, role limitations
due to emotional problems, mental health, energy/vitality,
pain, and general health perception. Health change over
the past year is also assessed. For each dimension of the
SF36v2, item scores are coded, summed and transformed
on a scale from 0 (worst possible health state measured by
questionnaire) to 100 (best possible health state).
The Zarit Burden Interview (ZBI) [33] is a 22-item
self-rating scale that examines the degree of burden
experienced by the carer associated with functional and
behavioural impairments of the person with AD. The
items are phrased subjectively and focus on the affective
response of the carer.
Measures administered by the PA RA
Resting blood pressure will be assessed after a five-minute
resting period, with five measurements taken at two-
minute intervals with a digital blood pressure monitor
(model UA-767PC, A&D Co., Ltd., Saitama, Japan).
Height, body weight, body composition and girths will
be measured in light clothing and bare feet. Height will
Table 1 Outline of the assessments and timelines of the FABS II
Assessment Tool Telephone Screen Baseline
(0 weeks)
Post-Intervention
(24 weeks)
12 months
(52 weeks)
Geriatric Depression Scale - 15 item X X X X
Cambridge Contextual Reading Test X
Alzheimer’s disease Assessment Scale - Cognitive section X X X
Standardized Mini-Mental State Examination X X X
Clinical Dementia Rating Scale XX X
Quality of Life - AD XX X
Neuropsychiatric Inventory XX X
Instrumental Activities of Daily Living X X X
Activities of Daily Living XX X
Short Form-36 version 2 (SF-36v2) X X X
Zarit Burden Interview XX X
Resting blood pressure XX X
Height, weight, body composition, girths X X X
Step test XX X
Sit-to-stand test XX X
Grip strength XX X
Timed Up and Go test XX X
Two-minute walk XX X
Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire X X X
Stages of Change XX X
Satisfaction with Life XX X
Self-Efficacy Questionnaire XX X
DNA sample collection X
The × indicates at which point of the trial the respective assessments took place. Follow-up times relate to baseline testing.
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composition (fat mass, fat free mass) will be assessed
using a bio-impedance analyzer, following the proce-
dures provided by the manufacturer (model TBF-300,
Tanita Corporation of America, Inc., Illinois, USA).
Waist and hip girths will be measured three times (med-
ian score used) using a retractable steel tape measure
(Lufkin W606PM Cooper industries SC, USA) [34].
A step test using a 7.5 cm square wooden block will
be used to assess dynamic balance [35]. The participant
places one foot on and off the block as many times as
possible in 15 seconds without using hand support. Per-
formance for each leg stepping is assessed separately,
and the lowest score will be recorded. The Timed Up
and Go (TUG) test will be used to assess mobility [36].
Participants will be seated in a chair with arms resting
on the arm rests and asked to get up and walk three
meters as fast and safely as they can, turn around and
return to a seated position. Functional lower limb
strength will be measured using the sit-to-stand test
(five chair stands) [37], with participants instructed to
s t a n du pa n ds i td o w na sq u i c k l ya sp o s s i b l ew i t ho r
without use of their arms. Maximum voluntary hand
grip strength (both hands) will be assessed using a
Smedleys dynamometer [34]. The participant will stand
against a wall. Holding the dynamometer vertically
above the head, the participant will be instructed to
squeeze as hard as possible while bringing the arm back
down to their side. A 2-minute walk around a 20-metre
measured course will be utilized to assess cardiovascular
endurance [38]. Participants will be instructed to walk
as fast as possible around the course as many times as
they can in two minutes. Participants will be allowed to
stop walking during the testing period if they needed to,
and any rests will be included in the total 2-minute test
period. The maximum distance walked, heart rate and
rate of perceived exertion [39] will be recorded.
Physical activity will be assessed using the Community
Healthy Activities Model Program for Seniors
(CHAMPS) physical activity questionnaire [40]. Assess-
ment will be made of the frequency, minutes, and cal-
orie expenditure per week of all, low, moderate, high
and very high intensity activities.
Participants will be provided with a pedometer (Digi-
Walker SW-200, Yamax Inc., Tokyo, Japan) and asked
to wear it for five weekdays and the weekend, following
the baseline visit, to objectively measure their weekly
PA. The pedometer will be put on immediately upon
wakening and taken off just before retiring at night. It
will also be removed whilst bathing or showering and
the time off recorded on the pedometer diary. Partici-
pants and carers will be shown how to wear and use the
pedometer and how to complete the diary. Participants
will be instructed to maintain their usual activity pattern
during the monitoring period.
The stage of PA behavior will be assessed using the
Stage of Change Instrument (SCI), a five-item question-
naire asking participants to indicate their current level
of activity [41]. The frequency and minutes per week of
regular moderate intensity PA will also be measured
using this questionnaire.
Exercise self-efficacy will be assessed with the five-
item Self-Efficacy Questionnaire (SEQ) asking partici-
pants how confident they were to exercise in certain
adverse conditions with responses on a 5-point scale
ranging from “not at all sure” to “very sure” [42].
Satisfaction with Life will be measured using a five-
item questionnaire with responses on a seven-point
scale ranging from “strongly disagree” to “strongly
agree” [43].
DNA Sample Collection
APOE genotyping will be performed at baseline testing
to adjust for APOE genotype in the final analysis and to
investigate whether there is an interaction between
APOE genotype and the benefits of PA influencing the
primary and secondary outcomes. Participants will be
asked to provide a 2 ml saliva sample using a DNA self-
collection kit (Oragene DNA OG-250 Disc Format,
DNA Genotek Inc, Ontario, Canada). They will be
stored at -80°C at the Department of Clinical Pathology
and Biochemistry at the Royal Perth Hospital. Samples
from Brisbane and Melbourne will be mailed to Perth.
All samples will be batched and processed once the final
baseline assessment has been completed.
Randomization and Blinding
Random allocation to intervention or control group will
be performed using Stata and the user-written program
ralloc [44]. Allocation numbers will be drawn by an
investigator not directly involved in the recruitment or
assessment of participants. Each of the three study sites
will be provided with sealed opaque envelopes num-
b e r e d1 - 1 0 0a n du s e di nt h a to r d e r .A f t e rap a r t i c i p a n t
completes his/her baseline assessment, the PA RA will
open the next consecutive envelope. Inside the envelope
there will either be the letter A (physical activity group)
or B (control group). Due to logistic difficulties, partici-
pants will not be blind to the intervention and sham PA
will not be used. However, the “clinical staff” involved in
the collection of endpoints will not be aware of group
allocation (single blind). Blinding will be supported by
the performance of cognitive and physical assessments
at different locations and explicit instructions to partici-
pants and clinical research staff not to discuss issues
related to PA during the assessments. The PA RA will
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phone and will instruct them not to share that informa-
tion with research staff involved in their future cognitive
assessments.
Intervention
The intervention period will be 24 weeks. The interven-
tion will comprise three components: the PA program,
the behavioral intervention package, and telephone
monitoring. Participants randomized to the intervention
will return with their carer ("coach”) for a PA workshop
within two to four weeks of their baseline visit. During
this 60-minute session, the PA RA will give participants
their program manual and explain the participants’ PA
program and the behavioral intervention package.
Physical activity program
Participants will be advised to perform at least 150 min/
week of moderate PA as per the new PA recommendations
for older people [45]. Where walking is a suitable and
acceptable option to the participant and coach, this will be
a primary PA recommendation. Examples will be given on
how this can be achieved. The program will be individua-
lized based on the CHAMPS and SCI data, and the per-
son’s interests. Activities prescribed will take into account
health problems or other limitations, and participants will
be instructed to start slowly and progress gradually taking
eight weeks to reach the target amount and intensity. Parti-
cipants will be encouraged to achieve the 150 min/week by
completing 3 × 50 minutes sessions (most PA classes range
between 45-60 minutes). In previous studies with middle-
aged and older women using this format, we have demon-
strated good retention, adherence and improvements in
cardiovascular fitness and blood pressure [46]. Participants
who already perform 150 min/week of PA will be encour-
aged to increase their PA by adding one 50-minute session.
To reduce the burden on coaches, some participants might
choose to complete activities in community centers. The
coach will be invited to perform physical activities along-
side participants, if appropriate.
In order to maintain standardization of the physical
activity programs one CI will monitor the programs pre-
scribed by the RA at each site. Further, to maintain
quality control another CI with a PA background will
review programs from a random selection on a regular
basis from all sites.
The PA program will include instructions on how to
read the program, complete the activities, record their
sessions, and exercise safely. Participants will be given a
simple diary and the coach will be asked to verify the
activity record the PA in the diary. The diaries, once
completed, will be retained by the participant and
returned at their six-month visit.
After the first 24 weeks, participants will be asked to
continue with their PA program for a further 24 weeks
however, there will be no further monitoring or contact
between the researchers and participants except for
three newsletters. At the end of 12 months, intervention
participants will be asked to complete a brief question-
naire regarding their program adherence for the pre-
vious six months.
Adherence during the six month active intervention
will be calculated from the number of sessions com-
pleted and recorded on the exercise diaries. This will be
expressed as a percentage of the number of sessions
completed relative to the number of sessions prescribed.
Behavioral Intervention
Participants and coaches will receive the same educa-
tional material about AD as the control group. The
intervention program will be based on the Stages of
Change model modified for PA [41], which has been
shown to be effective in increasing and maintaining PA
in middle-aged and older women [46]. This model pro-
poses that individuals move through five stages when
they adopt a new behavior. From participants’ SCI data,
a behavioral program will be developed to assist them to
move to the next stage of PA. Strategies to increase
adherence to the program will be discussed during the
workshop and worksheets will be included in a manual.
Topics will include tips on how to exercise, benefits and
costs of exercising, rewards of exercise, goal setting,
time management, etc.
During the 24-week trial, the PA RA will mail newslet-
ters at regular intervals to participants, which contain
additional motivational information. This will also be
reinforced during the five telephone calls made at regular
intervals. Participants and coaches will be contacted by
telephone for a standardized and structured 15- minute
interview to monitor and give feedback on their progress
and encourage their continuing adherence.
Participants will also be given a report after their fol-
low-up assessments. Giving feedback about progress and
increasing participants’ perceived benefits of being more
physically active has been shown to increase program
adherence [47].
Content and Program Evaluation
At the end of the intervention period, the intervention
group participants and the coach will be asked to com-
plete a brief interview questionnaire on the content and
processes of the program including how easy the pro-
gram was to understand and follow, and any barriers
that were encountered.
Control Group
Control group (usual care) participants and carers will
receive educational material about AD and recommen-
dations for a healthy lifestyle (other than PA). Partici-
pants will be contacted by telephone at the same
frequency as the intervention group to ensure that the
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except for the actual intervention. Conversation for this
group will be limited to their general health and will not
include discussion about physical activity. These activ-
ities, together with the benefit of follow-up assessments
will strengthen the adherence or ongoing participation
of the usual care group. At the conclusion of the study,
these participants will be offered the opportunity to
attend a session on PA.
Statistical Methods
Participants who drop out during the trial will be invited
to return for the follow-up assessments. We will use
imputation by chain equations (ICE) to estimate possible
missing outcomes in an intention-to-treat analysis (pri-
mary analysis). We will use multilevel regression models
to take into account repeated measures and intra-indivi-
dual variability (mixed models). These models will be
adjusted for confounding should the randomization pro-
duce unbalanced groups.
Sample Size and Power Calculation
In a pilot study conducted by this research team, the
ADAS-Cog score of participants in the control group
(usual care, n = 10) increased 4.47 ± 6.36 points in six
months (indicating cognitive decline) whereas the
patients in the intervention group (physical activity, n
= 12) increased 2.21 ± 4.88 points. Based on this pilot
data, recruiting 115 participants in each of the two
groups (total = 230) at baseline will result in a power
of 80% to detect a difference of 2.2 points between
the groups (alpha = 0.05, 2-tailed). This sample size
also allows for an estimated 15% drop out rate at
follow-up.
Discussion
Few RCTs have tested the effect of physical activity in
community dwelling people with AD, and none have
assessed the beneficial effects of physical activity in
terms of family caregiver burden and wellbeing [21]. By
building on the success of the FABS I trial involving
people with MCI [14], the FABS II study attempts to
address this gap in the literature. The study will also
evaluate the effectiveness of the strategies used to pro-
mote short-term and longer-term adherence to physical
activity in this population. The findings have the poten-
tial to inform practitioners about successful strategies
and provide the impetus for translation into community
programs. Further, the trial not only focuses on the par-
ticipant’s global cognitive and clinical symptoms, func-
tional level and quality of life but also on the indirect
positive effects that may be experienced by the care-
giver. From the 12-month follow-up assessment, we also
hope to provide evidence regarding the continuation of
such benefits.
Given the projected rising global incidence of AD over
the next several decades, the FABS II trial is timely. If
the current study protocol should prove successful, this
intervention will represent an affordable and safe
method, in combination with standard pharmacological
treatments, to alleviate the symptoms of AD. We antici-
pate that the results of this study will contribute to the
overall understanding and management of cognitive and
behavioural symptoms of AD as well as potentially
improving the quality of life of patients and their carers.
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